Related Experiment Video
Updated: May 16, 2026
Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
Published on: July 29, 2016
RNA interference targeting CUG repeats in a mouse model of myotonic dystrophy
Krzysztof Sobczak1, Thurman M Wheeler, Wenli Wang
1Department of Neurology, University of Rochester Medical Center, Rochester, New York 14642, USA. ksobczak@amu.edu.pl
Abstract:
Myotonic dystrophy type 1 (DM1) is an RNA dominant disease caused by expression of DM protein kinase (DMPK) transcripts that contain an expanded CUG repeat (CUG(exp)). The toxic mRNA localizes to nuclear foci and sequesters proteins involved in the regulation of alternative splicing, such as, muscleblind-like 1 (MBNL1). Here, we used synthetic short interfering RNAs (siRNAs) to target CUG repeats and test the concept that inhibiting the expression of CUG(exp) RNA can mitigate features of DM1 in transgenic mice. Intramuscular injection and electroporation of siRNA resulted in ~70-80% downregulation of CUG(exp) transcripts. A limited survey of endogenous mouse transcripts that contain nonexpanded CUG or CAG repeats showed that most were not affected, though Txlnb containing (CUG)(9) was significantly reduced. By this strategy, the number and intensity of CUG(exp) nuclear foci were reduced and splicing of MBNL1-dependent exons was improved. These data suggest that the expanded CUG repeats are a potential target for allele-selective RNA interference.
Insights
Targeting toxic CUG(exp) RNA in myotonic dystrophy type 1 (DM1) with short interfering RNAs (siRNAs) reduced disease features in mice. This approach offers a potential therapeutic strategy for DM1 by inhibiting disease-causing RNA transcripts.
Area of Science:
- Molecular Biology
- Genetics
- RNA Therapeutics
Background:
- Myotonic dystrophy type 1 (DM1) is an RNA dominant genetic disorder.
- It is characterized by expanded CUG repeats in the DM protein kinase (DMPK) gene.
- Toxic CUG(exp) RNA forms nuclear foci, sequestering splicing regulatory proteins like MBNL1.
Purpose of the Study:
- To investigate the efficacy of targeting CUG(exp) RNA using synthetic short interfering RNAs (siRNAs).
- To determine if inhibiting CUG(exp) RNA expression can mitigate DM1 features in a transgenic mouse model.
Main Methods:
- Utilized synthetic short interfering RNAs (siRNAs) designed to target expanded CUG repeats.
- Administered siRNAs via intramuscular injection and electroporation in DM1 transgenic mice.
- Quantified CUG(exp) transcript levels, nuclear foci, and MBNL1-dependent splicing patterns.
Main Results:
- Achieved significant ~70-80% downregulation of CUG(exp) transcripts.
- Observed a reduction in the number and intensity of CUG(exp) nuclear foci.
- Demonstrated improvement in MBNL1-dependent alternative splicing.
- Minimal impact on endogenous mouse transcripts with non-expanded CUG/CAG repeats was noted.
Conclusions:
- Expanded CUG repeats in DM1 are a viable therapeutic target for allele-selective RNA interference.
- siRNA-mediated inhibition of toxic CUG(exp) RNA can ameliorate key molecular and cellular features of DM1.
- This strategy holds promise for developing novel treatments for myotonic dystrophy type 1.
